Identifying Novel Therapies for Multiple Myeloma: Paul Richardson, MD

In the following interview, Dr. Paul Richardson, the Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, discusses some important factors in the development of drugs to target "the queen of immunological cancers," multiple myeloma, and why this disease is difficult to cure. Recently, he led the development and clinical trials of the novel targeted cytotoxic peptide-drug, melphalan flufenamide (Pepaxto®, Oncop...
Continue reading

Lisocabtagene Maraleucel Approved for Relapsed/Refractory Large B-Cell Lymphomas

The FDA has approved lisocabtagene maraleucel (Breyanzi®, Juno Therapeutics) for patients with relapsed/refractory large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DCBLC transformed from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, and grade 3B follicular lymphoma, who have progressive disease following at least two prior lines of systemic therapy. Lisocabtagene maraleucel is not indicated for patie...
Continue reading

Vitamin D Supplements for Reducing Advanced Cancer Risk: Paulette Chandler, MD, MPH

In a study recently published in JAMA Network Open, a team of investigators led by Paulette Chandler, MD, MPH, found that vitamin D supplementation is associated with a decreased risk of developing advanced cancer, particularly among individuals with a normal body mass index (BMI). In this interview with i3 Health, Dr. Chandler, an Assistant Professor of Medicine at Harvard Medical School, discusses the significance of these results and the ongoing research investigating vitamin D supplementatio...
Continue reading

Vitamin D Supplements May Reduce the Risk of Developing Advanced Cancer

In individuals without cancer, vitamin D supplementation may decrease the risk of developing advanced cancer, especially for those with a normal body mass index (BMI), according to a recent analysis of a phase 3 trial. "Vitamin D may decrease tumor invasiveness and propensity to metastasize, leading to reduced cancer mortality," write the investigators, led by first author Paulette D. Chandler, MD, MPH, Assistant Professor of Medicine at Harvard Medical School. "Vitamin D may have a role in redu...
Continue reading

Nivolumab/Ipilimumab for Advanced Renal Cell Carcinoma: Meredith Regan, ScD

Patients with advanced renal cell carcinoma (RCC) who receive combination PD-1/CTLA-4 blockade can experience periods of durable benefit and toxicity after treatment discontinuation. According to results of the phase 3 CheckMate 214 trial presented by Meredith Regan, ScD, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, nivolumab/ipilimumab prolongs treatment-free survival, both with and without toxicity, in patients with previously untreated advanced clear cell RCC. In...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.